Jocelyn de Heer
Dr. med.
Jocelyn de Heer
  • Senior physician
  • Fachärztin für Innere Medizin, Gastroenterologie und Endokrinologie
Working area
Contact
Phone
+49 (0) 40 7410 - 0
Telefax
+49 (0) 40 7410 - 44420
E-mail
j.deheer@uke.de
Location
Main Building O10 , 2nd Floor, Room number 02.4.070.1
Languages
German (Mother tongue)
English

Areas of expertise

  • Endocrinology

  • Gastroenterology

Memberships

  • Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)

  • Deutsche Gesellschaft für Innere Medizin (DGIM)

Publications

  • de Heer J (2016) Kohlenhydratstoffwechsel der Leber. Der Diabetologe, Nov 12(7): 461-467

  • de Heer J, Göke B (2014) Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas? Expert Opin Drug Saf. Nov;13(11):1469-81.

  • Aulinger B, Bedorf A, Kutscherauer G, de Heer J, Holst JJ, Göke B, Schirra J (2014) Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes. Mar 63(3):1079-92.

  • de Heer J, Parhofer K (2013) [Antidiabetic drug therapy in overweight and obese adults with type 2 diabetes]. MMW Fortschr Med. Apr 18;155(7):43-6

  • de Heer J (2012) Adipositas, metabolisches Syndrom und Krebsentstehung. Der Diabetologe Sept 8 (6): 455-462

  • Holst JJ, Christensen M, Lund A, de Heer J, Svendsen B, Kielgast U, Knop FK (2011) Regulation of glucagon secretion by incretins. Diabetes Obes Metab. Oct;13 Suppl 1:89-94

  • de Heer J, Rasmussen C, Coy DH, Holst JJ (2008) Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51(12):2263-70

  • de Heer J, Pedersen J, Ørskov C, Holst JJ (2007) The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from rat pancreas. Diabetologia 50(10):2135-42

  • de Heer J, Holst JJ (2007) Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-like Peptide (GLP) -1. Diabetes 56(2):438-443

  • Deacon CF, Plamboeck A, Rosenkilde MM, de Heer J, Holst JJ (2006) GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. Am J Physiol Endocrinol Metab 291(3):468-475

Back